Amphastar Pharmaceuticals (AMPH) stock
Members see every stock ranked and every check behind each score, live.
Why AMPH scores 10
AverageTrending up, 6 of 13 possible checks firingWhat the Quality Score means
Well above its own recent run. AMPH scores 10 today, against a median of 6 over its last 20 recorded sessions.
- +6Momentum traits 6 firing right now, of 13 possible, one point each
- +2Long-term trend above a rising 200-day, near its 52-week high, down over two years
- Run-up adds
- Profit adds
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed -10.1% on average, higher 1 of 4 times.
What would move AMPH's score: 6 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
AMPH has 6 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How AMPH ranks in Biotech
AMPH is #40 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
RGEN8/1320
HALO8/1320
ABCL9/1319
EXELOpen for its score
XERSOpen for its score
AMPH6/1310
When does AMPH report, and what happens after?
Expected to report Thu Nov 5, after the close (in 38 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +13.5% | +4.9% | +1.9% |
| May 7, 2026After close | After close | -22.7% | -20.9% | -28.0% |
| Feb 26, 2026After close | After close | -15.3% | -23.6% | -22.8% |
| Nov 6, 2025After close | After close | +7.9% | -0.8% | +8.8% |
Who is trading AMPH
Insiders
2 insiders sold $477K across 3 filings in the last 6 months. No open-market buys on record. The newest:
Congress and the White House
One trade disclosed in the last six months. The newest:
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of AMPH's score, with the points and the reason
- All 14 checks on AMPH and on all 2,951 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on AMPH
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.